TLDR
- UnitedHealth Group will meet with investors Monday through Wednesday to reaffirm its adjusted 2025 earnings outlook
- Company expects at least $16.00 per share in adjusted earnings, below analyst consensus of $16.24
- The outlook includes the recently completed Amedisys acquisition, expected to be modestly dilutive
- Shares rose 1.3% in premarket trading following the announcement
- Company projects total revenue between $445.5 billion and $448.0 billion for 2025
UnitedHealth Group will spend three days this week reassuring Wall Street about its financial prospects. The health insurance giant announced plans to meet with investors and analysts from Monday through Wednesday to discuss its 2025 earnings expectations.
The company will reaffirm its adjusted earnings per share outlook of at least $16.00, first announced on July 29. This figure sits below the $16.24 consensus estimate from analysts.
Shares jumped 1.3% in premarket trading on Monday following the announcement. The stock has faced pressure throughout 2025 as rising medical costs have squeezed profit margins.
UnitedHealth’s earnings outlook now incorporates the completed acquisition of Amedisys in August. The home healthcare company purchase is expected to reduce earnings per share due to financing costs and integration expenses.
The company projects total revenue between $445.5 billion and $448.0 billion for the full year. Current analyst estimates call for revenue of $448.2 billion.
Recent Challenges Drive Investor Concerns
UnitedHealth has navigated several headwinds this year that have weighed on investor sentiment. Medical costs have risen faster than expected, particularly in the company’s Medicare Advantage business.
The insurer’s medical expense ratio has climbed to historic levels. This key metric measures how much of collected premiums goes toward paying medical claims.
More seniors have been using their insurance benefits than the company had planned. This increased utilization has created unexpected expenses across the healthcare sector.
Company leadership may discuss strategy and market positions during this week’s meetings. These discussions will remain consistent with previous public disclosures.
Acquisition Impact and Integration Costs
The Amedisys deal closed in August after receiving regulatory approval. UnitedHealth paid approximately $3.3 billion for the home healthcare provider.
Integration costs will temporarily reduce earnings per share. The company expects these expenses to moderate as the acquisition becomes fully incorporated.
Financing costs for the deal also contribute to the modest dilutive impact. UnitedHealth used a combination of cash and debt to complete the purchase.
The acquisition expands the company’s presence in home healthcare services. This market has grown as more patients receive care outside traditional hospital settings.
UnitedHealth filed the investor meeting information under Regulation FD Disclosure with the Securities and Exchange Commission. The company noted that forward-looking statements carry risks and uncertainties.
Actual results may differ from current expectations due to various factors. The healthcare industry continues to face evolving challenges around medical costs and utilization patterns.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:
- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support
